HALO

Q: What is the price of Halozyme Therapeutics (HALO) today?

The price of Halozyme Therapeutics (HALO) today is R$ 395,38, with a variation of 17.36% compared to the last year. The price of Halozyme Therapeutics (HALO) started the year trading around R$ 259,13 and today it is at R$ 395,38. Follow the real-time price chart, the historical price of Halozyme Therapeutics (HALO), and stock data from Ibovespa and international markets.

Q: When does Halozyme Therapeutics (HALO) pay dividends?

Halozyme Therapeutics (HALO) did not distribute dividends in the last year.

Q: Halozyme Therapeutics (HALO) is it worth it?

Currently, Halozyme Therapeutics (HALO) is priced at R$ 395,38, with a P/E of 15,59%, representing a deviation of 19,90% from its historical average P/E. In the last year, the stock showed a variation of 17.36% in its price and distributed R$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was 17,36%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How to buy shares of Halozyme Therapeutics (HALO)?

Investing in shares of Halozyme Therapeutics (HALO) can be done in two ways: by buying the stock abroad or the BDR in Brazil (if available). The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.The BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much do 100 shares of Halozyme Therapeutics (HALO) yield today?

The yield of Halozyme Therapeutics (HALO) was 25,26% in the last month, 17,36% in the last year and 156,50% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of R$ 0,00 in dividends, um Dividend Yield de 0,00%.If you wanted to buy 100 shares of Halozyme Therapeutics (HALO) today, the total investment would be based on the current price of R$ 395,38.If past performance were to repeat, the return on your investment would be:In 1 year: R$ 46.402,22In 5 years: R$ 101.415,89In 10 years: 165.195,21It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Halozyme Therapeutics Inc.

Price

US$ 72,95

variation (12m)

17,36%

p/l

15,59

p/vp

26,12

DIVIDEND YIELD

0,00%

quote HALO

BVMF

HALO

If you had invested

year ago

6 months

1 year

5 years

10 years

today you would have

today you would have:

*The figure considers the reinvestment of dividends.

profitability of HALO

1 month

3 months

1 year

2 years

5 years

10 years

profitability

1 month

25,26%

3 months

34,02%

1 year

17,36%

2 years

71,89%

5 years

156,50%

10 years

317,81%

real profitability

profitability minus inflation.

1 month

25,26%

3 months

33,35%

1 year

11,51%

2 years

56,68%

5 years

87,42%

10 years

147,69%

Indicators HALO

check out the fundamentals of Halozyme Therapeutics shares

P/L

15,59

Sector: -3,27 Industry: -3,27

P/SALES (PSR)

7,37

Sector: -3,77 Industry: -3,77

P/VP

26,12

Sector: 1,74 Industry: 1,74

DIVIDEND YIELD (DY)

0,00%

Sector: - Industry: -

ROA

27,13%

Sector: -63,50% Industry: -63,50%

ROE

167,47%

Sector: -67,23% Industry: -67,23%

ROIC

48,89%

Sector: -2.087,74% Industry: -2.087,74%

Net Margin

47,28%

Sector: -43,34% Industry: -43,34%

GROSS MARGIN

84,20%

Sector: 40,50% Industry: 40,50%

OPERATING MARGIN

57,92%

Sector: -43,21% Industry: -43,21%

P/EBITDA

10,97

Sector: -3,13 Industry: -3,13

P/EBIT

12,24

Sector: -3,41 Industry: -3,41

P/ASSETS

4,23

Sector: 1,29 Industry: 1,29

VPA

2,75

Sector: 1,80 Industry: 1,80

LPA

4,61

Sector: -2,09 Industry: -2,09

EQUITY / ASSETS

0,16

Sector: 0,42 Industry: 0,42

CAGR REVENUES 5 YEARS

34,52%

Sector: - Industry: -

CAGR PROFITS 5 YEARS

33,98%

Sector: - Industry: -

FAIR PRICE OF Halozyme Therapeutics ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Price

The Fair Price formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

US$ 72,95

Fair Price

US$ 0,00

Upside Potencial de rentabilidade.

-76,85%

See Graham's ranking

Because it considers equity value in its calculation, the formula does not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

HALO indicators history

DRAG THE FRAME TO SEE MORE DATA

comparator of Stocks

DRAG THE FRAME TO SEE MORE DATA

	p/l	p/vp	ROE	dy	market value	Net Margin
JNJ	19,04	5,50	28,88%	2,80%	US$ 431,37 B	25,00%
PFE	13,45	1,62	12,08%	6,68%	US$ 144,63 B	16,84%
ABBV	79,66	228,58	286,94%	3,38%	US$ 334,19 B	7,31%
NVO	15,51	9,75	62,86%	2,83%	US$ 253,39 B	35,63%
MRK	13,05	4,36	33,44%	3,75%	US$ 214,13 B	25,79%
BMY	19,31	5,58	28,87%	5,13%	US$ 97,52 B	10,58%
GILD	22,64	7,29	32,21%	2,72%	US$ 142,89 B	21,87%
AZN	30,26	5,60	18,51%	1,91%	US$ 251,01 B	14,68%
ZTS	26,68	14,00	52,48%	1,19%	US$ 69,70 B	27,83%
REGN	13,88	2,07	14,89%	0,30%	US$ 61,90 B	31,37%
AMGN	23,87	21,27	89,11%	3,15%	US$ 158,02 B	18,96%
VRTX	27,92	5,91	21,18%	0,00%	US$ 101,55 B	31,86%
ADMA	20,53	10,77	52,45%	0,00%	US$ 4,29 B	44,06%
MCK	27,24	-99,86	-366,63%	0,41%	US$ 86,18 B	0,84%
BIIB	13,38	1,16	8,68%	0,00%	US$ 20,48 B	15,31%
CAH	22,58	-13,38	-59,26%	1,37%	US$ 35,25 B	0,70%
HRMY	11,93	2,79	23,40%	0,00%	US$ 2,16 B	23,42%

comparison of HALO with indexes

If you had invested (change) 2 years a year ago, today you would have

R$ 1.000,00 in PETR4 you would have R$ 2.294,60

R$ 1.000,00 in LEVE3 you would have R$ 5.240,60

*The value considers the reinvestment of dividends.

dividend history HALO dividend history

Current DY: 0,00%

5-year average DY: 0,00%

no dividend paid in the period.

ABOUT THE COMPANY Halozyme Therapeutics

Halozyme Therapeutics Inc.

Average user rating I10

4.0 (44 people)

Estados Unidos

27 years

Foundation: 1998

2004

Year of debut on the stock exchange - 21 years

132

Employees

Additional Information

The Company Halozyme Therapeutics Inc. (Estados Unidos), is listed on Nasdaq with a market value of $ 8,69 Billions, having a net worth of $ 332,75 Milhões.

With a total of 132 employees, the company is listed in the sector of Cuidados de saúde and categorized in industry of Biotecnologia.

In the last 12 months the Company had a revenue of $ 1,18 Billion, which generated a profit in the amount of $ 557,27 Milhões.

As for its main indicators, the Company has a P/E ratio of 15,59, a P/B ratio of 26,12 and in the last 12 months the Company did not pay dividends.

The Company is traded through the ticker HALO.

Market value

US$ 8,69 Billions

Net worth

US$ 332,75 Milhões

US$ 332.750.000,00

Assets

US$ 2,05 Billions

US$ 2.053.900.000,00

Total Number of Shares

121,00 Milhões

121.000.000

Average Daily Trading Volume

US$ 2,25 Milhões

US$ 2.248.602,00

Sector

Cuidados de saúde

Industry

Biotecnologia

HALO

HALO revenue and profits

HALO results

DRAG THE FRAME TO SEE MORE DATA

HALO cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

US$ - -0,00% (12M)

P/L

0,00

0,00%

ROE

-893,55%

P/VP

0,00

MCK - McKesson

US$ 680,52 24,27% (12M)

P/L

27,24

0,41%

ROE

-366,63%

P/VP

-99,86

CAH - Cardinal Health

US$ 147,49 36,56% (12M)

P/L

22,58

1,37%

ROE

-59,26%

P/VP

-13,38

JNJ - Johnson & Johnson

US$ 176,49 12,66% (12M)

P/L

19,04

2,80%

ROE

28,88%

P/VP

5,50

MRK - Merck & Co.

US$ 84,99 --23,85% (12M)

P/L

13,05

3,75%

ROE

33,44%

P/VP

4,36

PFE - Pfizer

US$ 24,92 --5,92% (12M)

P/L

13,45

6,68%

ROE

12,08%

P/VP

1,62

AZN - AstraZeneca

US$ 80,05 --5,68% (12M)

P/L

30,26

1,91%

ROE

18,51%

P/VP

5,60

ABBV - AbbVie

US$ 208,36 10,15% (12M)

P/L

79,66

3,38%

ROE

286,94%

P/VP

228,58

BFRA - Biofrontera

US$ - -0,00% (12 M)

P/L

0,00

0,00%

ROE

-893,55%

P/VP

0,00

MCK - McKesson

US$ 680,52 24,27% (12 M)

P/L

27,24

0,41%

ROE

-366,63%

P/VP

-99,86

CAH - Cardinal Health

US$ 147,49 36,56% (12 M)

P/L

22,58

1,37%

ROE

-59,26%

P/VP

-13,38

JNJ - Johnson & Johnson

US$ 176,49 12,66% (12 M)

P/L

19,04

2,80%

ROE

28,88%

P/VP

5,50

MRK - Merck & Co.

US$ 84,99 --23,85% (12 M)

P/L

13,05

3,75%

ROE

33,44%

P/VP

4,36

PFE - Pfizer

US$ 24,92 --5,92% (12 M)

P/L

13,45

6,68%

ROE

12,08%

P/VP

1,62

AZN - AstraZeneca

US$ 80,05 --5,68% (12 M)

P/L

30,26

1,91%

ROE

18,51%

P/VP

5,60

ABBV - AbbVie

US$ 208,36 10,15% (12 M)

P/L

79,66

3,38%

ROE

286,94%

P/VP

228,58

Common Questions

What is the price of Halozyme Therapeutics (HALO) today?

The price of Halozyme Therapeutics (HALO) today is R$ 395,38, with a variation of 17.36% compared to the last year. The price of Halozyme Therapeutics (HALO) started the year trading around R$ 259,13 and today it is at R$ 395,38. Follow the real-time price chart, the historical price of Halozyme Therapeutics (HALO), and stock data from Ibovespa and international markets.

When does Halozyme Therapeutics (HALO) pay dividends?

Halozyme Therapeutics (HALO) did not distribute dividends in the last year.

Halozyme Therapeutics (HALO) is it worth it?

Currently, Halozyme Therapeutics (HALO) is priced at R$ 395,38, with a P/E of 15,59%, representing a deviation of 19,90% from its historical average P/E. In the last year, the stock showed a variation of 17.36% in its price and distributed R$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was 17,36%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How to buy shares of Halozyme Therapeutics (HALO)?

Investing in shares of Halozyme Therapeutics (HALO) can be done in two ways: by buying the stock abroad or the BDR in Brazil (if available). The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

The BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much do 100 shares of Halozyme Therapeutics (HALO) yield today?

The yield of Halozyme Therapeutics (HALO) was 25,26% in the last month, 17,36% in the last year and 156,50% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of R$ 0,00 in dividends, um Dividend Yield de 0,00%.

If you wanted to buy 100 shares of Halozyme Therapeutics (HALO) today, the total investment would be based on the current price of R$ 395,38.

If past performance were to repeat, the return on your investment would be:

In 1 year: R$ 46.402,22
In 5 years: R$ 101.415,89
In 10 years: 165.195,21

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

HALO

Halozyme Therapeutics Inc.

Price

variation (12m)

p/l

p/vp

DIVIDEND YIELD

profitability of HALO

check out the fundamentals of Halozyme Therapeutics shares

P/L

P/SALES (PSR)

P/VP

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

Net Margin

GROSS MARGIN

OPERATING MARGIN

P/EBITDA

P/EBIT

P/ASSETS

VPA

LPA

EQUITY / ASSETS

CAGR REVENUES 5 YEARS

CAGR PROFITS 5 YEARS

Graham's Fair Price

If you had invested (change) 2 years a year ago, today you would have

Current DY: 0,00%

5-year average DY: 0,00%

ABOUT THE COMPANY Halozyme Therapeutics

Halozyme Therapeutics Inc.

Estados Unidos

27 years

2004

132

Additional Information

PROFIT X PRICE HALO

HALO results

HALO cash flow

evolution of assets - HALO

HALO balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

PFE - Pfizer

AZN - AstraZeneca

ABBV - AbbVie

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

PFE - Pfizer

AZN - AstraZeneca

ABBV - AbbVie

Common Questions

Tudo que o investidor precisa em um só lugar

Pague 2, Leve 3

Anual

Valor total R$ 238,80